Generic Name: Pletal

What is Pletal?

This website also contains material copyrighted by 3rd parties. Share a CaseThis drug is available at a middle level co-pay. This drug is available at a higher level co-pay.

Prior Authorization Drugs that require prior authorization. Quantity Limits Drugs that have quantity limits associated with each prescription. Step Therapy Drugs that have step therapy associated with each prescription.

Other Restrictions Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription. Cilostazol is a quinolinone-derivative medication used in the alleviation of the symptoms of intermittent claudication in individuals with peripheral vascular disease. It is manufactured by Otsuka Pharmaceutical Co. Although drugs similar to cilostazol have increased the risk of death in patients with congestive heart failure, studies of significant size have not addressed people without the disease.

Cilostazol is a phosphodiesterase inhibitor with therapeutic focus on cyclic adenosine monophosphate cAMP. It inhibits platelet aggregation and is a direct arterial vasodilator.

The signs and symptoms of an acute overdose can be anticipated to be those of excessive pharmacologic effect: severe headache, diarrhea, hypotension, tachycardia, and possibly cardiac arrhythmias.

The patient should be carefully observed and given supportive treatment. Since cilostazol is highly protein-bound, it is unlikely that it can be efficiently removed by hemodialysis or peritoneal dialysis.

The oral LD50 of cilostazol is greater than 5 g per kg in mice and rats and greater than 2 g per kg in dogs. PLETAL and several of its metabolites inhibit phosphodiesterase III activity and suppress cAMP degradation with a resultant increase in cAMP in platelets and blood vessels, leading to inhibition of platelet aggregation and vasodilation, respectively.

PLETAL reversibly inhibits platelet aggregation induced by a variety of stimuli, including thrombin, ADP, collagen, arachidonic acid, epinephrine, and shear stress. In humans, heart rate increased in a dose-proportional manner by a mean of 5. Cilostazol's effects on platelet aggregation were evaluated in both healthy subjects and in patients with stable symptoms of cerebral thrombosis, cerebral embolism, transient ischemic attack, or cerebral arteriosclerosis over a range of doses from 50 mg every day to 100 mg three times a day.

Cilostazol significantly inhibited platelet aggregation in a dose-dependent manner. The effects were observed as early as 3 hours post-dose and lasted up to 12 hours following a single dose.

Following chronic administration and withdrawal of cilostazol, the effects on platelet aggregation began to subside 48 hours after withdrawal and returned to baseline by 96 hours with no rebound effect. A cilostazol dosage of 100 mg twice daily consistently inhibited platelet aggregation induced with arachidonic acid, collagen and adenosine diphosphate ADP.

Bleeding time was not affected by cilostazol administration. Effects on circulating plasma lipids have been examined in patients taking PLETAL. After 12 weeks, as compared to placebo, PLETAL 100 mg twice daily produced a reduction in triglycerides of 29.

How should I take Pletal?

OVERDOSE: If overdose is suspected, contact a poison control center or emergency room immediately. For information about enrolling in MedicAlert, call 1-800-854-1166 US or 1-800-668-1507 Canada. Information last revised November 2010 Copyright c 2010 First DataBank, Inc. Learn more about Rx Outreach About Rx Outreach Rx Outreach is a non-profit pharmacy whose mission is to provide affordable medications to people in need.

No one should ever have to choose between filling a prescription and feeding their family. Rx Outreach offers more than 600 medication strengths, representing more than 250 different types of medications. There are many online pharmacies that claim to offer cheap drugs.

What should I avoid while taking Pletal?

This information is not specific medical advice and does not replace information you receive from your health care provider. You must talk with your healthcare provider for complete information about the risks and benefits of using Pletal. Disclaimer: This information should not be used to decide whether or not to take this medicine or any other medicine. This is only a brief summary of general information about this medicine. It does NOT include all information about the possible uses, directions, warnings, precautions, interactions, adverse effects, or risks that may apply to this medicine.

Pletal side effects

A dosage of 50 mg PO twice daily should be considered for patients concomitantly receiving inhibitors of CYP3A4 or CYP2C19. A dosage of 100 mg PO twice daily has been suggested. One trial in 70 patients demonstrated that cilostazol treatment resulted in lower restenosis rates 8. Dose adjustments do not appear necessary in patients with mild, stable hepatic impairment. Cilostazol has not been studied in patients with moderate to severe hepatic disease.

Dose adjustments do not appear to be necessary for patients with mild to moderate renal impairment i. Intermittent hemodialysisNo in vivo data are available.

Common Pletal ide effects may include:

  • Pletal and PregnancyBack to TopTell your doctor if you are pregnant or plan to become pregnant.

  • You should not use the information contained herein for diagnosing or treating a health problem or disease, or prescribing any medication.

  • However, caution is advised in patients receiving both cilostazol and any anticoagulant agent, and frequent monitoring is required to reduce the possibility of bleeding.

  • Common side effects of platelet inhibitors include headache, dizziness, and vomiting.

Because of this, we urge users to be extra vigilant when taking the drug and report the effects or lack of it to their doctor to assess whether staying on with the medication is the best option. Johnson TagsCilostazol Intermittent Claudication Japan Otsuka Pharmaceutical Pletal About Sam W.

Johnson Working in pharmacology for a long time, Sam gained knowledge and experience which he shares in his product reviews. His great skills of finding and analyzing information help him in writing short, solid and useful reviews. Rendez-vous dans nos forums.

Where can I get more information?

  • Correlation of improvement in walking distances with improvement in QoL SF-36 and WIQ outcomes An analysis of patient rated treatment success with cilostazol compared with placebo Expert opinion Prof Dawson 2009.

  • A dosage of 100 mg PO twice daily has been suggested.